Interpace Biosciences®, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Stock-Based Compensation (Tables)

Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2014

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]



	December 31, 2014		December 31, 2013
Risk-free interest rate	0.75	%	0.33	%
Expected life	3.5		3.5
Expected volatility	48.15	%	49.80	%

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]

The impact of stock options, SARs, performance shares, RSUs and restricted stock on net loss for the years ended December 31, 2014 and 2013 is as follows:



	2014		2013
Stock options and SARs	$	727	$	454
Performance awards	98		—
RSUs and restricted stock	1,299		1,269
Total stock-based compensation expense	$	2,124	$	1,723

Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value [Table Text Block]

A summary of stock option and SARs activity for the year ended December 31, 2014, and changes during such year, is presented below:



	Shares		Average Grant Price	Remaining Contractual Period (in years)	Aggregate Intrinsic Value
Outstanding at January 1, 2014	838,543		$6.52	3.08	$	148
Granted	925,410		$4.33	4.31	$	—
Exercised	—		—
Forfeited or expired	(71,032	)	$11.47
Outstanding at December 31, 2014	1,692,921		$5.12	3.40	$	4
Exercisable at December 31, 2014	437,356		$6.32	1.82	$	—
Vested and expected to vest	1,456,345		$5.12	3.32	$	3

Schedule of Share-based Compensation, Stock Appreciation Rights Award Activity [Table Text Block]

A summary of the status of the Company’s nonvested SARs for the year ended December 31, 2014, and changes during such year, is presented below:



	Shares		Weighted- Average Grant Date Fair Value
Nonvested at January 1, 2014	544,573		$	2.20
Granted	925,410		$	1.56
Vested	(208,345	)	$	2.27
Forfeited	(6,073	)	$	1.97
Nonvested at December 31, 2014	1,255,565		$	1.72

Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]

A summary of the Company’s nonvested shares of restricted stock and restricted stock units for the year ended December 31, 2014, and changes during such year, is presented below:



	Shares		Weighted- Average Grant Date Fair Value		Average Remaining Vesting Period (in years)	Aggregate Intrinsic Value
Nonvested at January 1, 2014	581,709		$	4.81	1.44	$	2,660
Granted	402,648		$	3.76	2.48	$	721
Vested	(213,295	)	$	7.83
Forfeited	(60,059	)	$	5.22
Nonvested at December 31, 2014	711,003		$	2.81	1.70	$	1,273

- Definition

Tabular disclosure of components of a stock option or other award plan under which equity-based compensation is awarded to employees, typically comprised of the amount of unearned compensation (deferred compensation cost), compensation expense, and changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan. Disclosure may also include nature and general terms of such arrangements that existed during the period and potential effects of those arrangements on shareholders, effect of compensation cost arising from equity-based payment arrangements on the income statement, method of estimating the fair value of the goods or services received, or the fair value of the equity instruments granted, during the period, cash flow effects resulting from equity-based payment arrangements and, for registrants that accelerate vesting of out of the money share options, reasons for the decision to accelerate.

+ References + Details